MX2013006732A - 19-noresteroides novedosos y su uso para tratar condiciones que dependen de progesterona. - Google Patents

19-noresteroides novedosos y su uso para tratar condiciones que dependen de progesterona.

Info

Publication number
MX2013006732A
MX2013006732A MX2013006732A MX2013006732A MX2013006732A MX 2013006732 A MX2013006732 A MX 2013006732A MX 2013006732 A MX2013006732 A MX 2013006732A MX 2013006732 A MX2013006732 A MX 2013006732A MX 2013006732 A MX2013006732 A MX 2013006732A
Authority
MX
Mexico
Prior art keywords
steroids
novel
treating
dependent conditions
conditions
Prior art date
Application number
MX2013006732A
Other languages
English (en)
Inventor
Joseph S Podolski
Ronald D Wiehle
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2010/062068 external-priority patent/WO2011119194A1/en
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of MX2013006732A publication Critical patent/MX2013006732A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

El objeto de la presente invención es pertinente para el campo de tratamiento de condiciones que dependen de hormonas. Se describen nuevos compuestos y métodos para tratar estas condiciones. Las modalidades de la presente invención describen métodos para tratar endometriosis, dismenorrea, cáncer de seno, fibroides uterina e hiperproliferación endometrial.
MX2013006732A 2010-12-23 2011-09-08 19-noresteroides novedosos y su uso para tratar condiciones que dependen de progesterona. MX2013006732A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2010/062068 WO2011119194A1 (en) 2010-03-22 2010-12-23 Compositions and methods for non-toxic delivery of antiprogestins
PCT/US2011/050859 WO2012087389A1 (en) 2010-12-23 2011-09-08 Novel 19-nor-steroids and their use for treating progesterone-dependent conditions

Publications (1)

Publication Number Publication Date
MX2013006732A true MX2013006732A (es) 2013-07-17

Family

ID=44681424

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006732A MX2013006732A (es) 2010-12-23 2011-09-08 19-noresteroides novedosos y su uso para tratar condiciones que dependen de progesterona.

Country Status (13)

Country Link
US (1) US20130274234A1 (es)
EP (1) EP2655394A1 (es)
JP (2) JP2014500316A (es)
KR (1) KR20130132955A (es)
CN (1) CN103403017A (es)
AU (1) AU2011345341B2 (es)
CA (1) CA2820877A1 (es)
MX (1) MX2013006732A (es)
NZ (1) NZ612295A (es)
SG (1) SG191207A1 (es)
UA (1) UA113283C2 (es)
WO (1) WO2012087389A1 (es)
ZA (1) ZA201304381B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ702467A (en) 2012-05-31 2016-07-29 Repros Therapeutics Inc Formulations and methods for vaginal delivery of antiprogestins
CN104755087A (zh) * 2012-11-02 2015-07-01 利普生物药剂公司 治疗孕酮依赖性病况的方法和组合物
CA2948287A1 (en) * 2014-05-05 2015-11-12 Repros Therapeutics Inc. Formulations and methods for vaginal delivery of antiprogestins

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
US4615697A (en) 1983-11-14 1986-10-07 Bio-Mimetics, Inc. Bioadhesive compositions and methods of treatment therewith
FR2573657B1 (fr) * 1984-11-29 1989-05-12 Roussel Uclaf Produit comprenant une substance antiprogestomimetique et une substance uterotonique
US4954490A (en) * 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
CA2668824A1 (en) * 1996-05-01 1997-11-06 The Government Of The United States Of America, Represented By The Secre Tary Of The Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
US6020328A (en) * 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
AU4584901A (en) * 2000-03-17 2001-10-15 Us Gov Health & Human Serv Structural modification of 19-norprogesterone i: 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
EA017227B1 (ru) * 2006-10-24 2012-10-30 Репрос Терапьютикс Инк. Способ лечения эстрогензависимого состояния
WO2009061569A1 (en) * 2007-11-05 2009-05-14 Repros Therapeutics Inc. Compositions and methods for treating dysfunctional uterine bleeding
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
TWI539953B (zh) * 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法

Also Published As

Publication number Publication date
AU2011345341B2 (en) 2016-10-20
US20130274234A1 (en) 2013-10-17
UA113283C2 (xx) 2017-01-10
NZ612295A (en) 2014-07-25
CA2820877A1 (en) 2012-06-28
KR20130132955A (ko) 2013-12-05
AU2011345341A1 (en) 2013-07-04
SG191207A1 (en) 2013-07-31
WO2012087389A1 (en) 2012-06-28
CN103403017A (zh) 2013-11-20
EP2655394A1 (en) 2013-10-30
JP2014500316A (ja) 2014-01-09
JP2016180004A (ja) 2016-10-13
ZA201304381B (en) 2014-03-26

Similar Documents

Publication Publication Date Title
PH12017502141A1 (en) Compounds and their methods of use
IN2014KN00848A (es)
MX2014009751A (es) Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
MX2020010639A (es) Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer.
CL2015001508A1 (es) Compuestos derivados de bencimidazol, antagonistas de receptores ep4; composicion farmaceutica; combinacion farmaceutica; uso para tratar y/o prevenir enfermedades tales como endometriosis, hemorragias uterinas, dismenorrea, canceres de pulmon, de intestino, de mama, de prostata, entre otros.
EA201491412A1 (ru) Соединения для лечения спинальной мышечной атрофии
MX370535B (es) Compuestos de tetrahidroquinolina como inhibidores del bromodominio extra terminal y bromo (bet) y el uso de los mismos en el tratamiento de cáncer.
NZ726859A (en) Synthesis of polycyclic-carbamoylpyridone compounds
EA201792465A1 (ru) Соединения для лечения спинальной мышечной атрофии
MX2016004570A (es) Uso de inhibidores del bromodominio de cbp/ep300 para la inmunoterapia del cáncer.
EA201490944A1 (ru) Двойной ингибитор met и vegf для лечения рака
PH12015501243A1 (en) Compositions and methods for antibodies targeting epo
PH12015501997A1 (en) Compositions and methods for diagnosis and treatment of hepatic cancers
MY164622A (en) Compositions and methods for non-toxic delivery of antiprogestins
TN2012000469A1 (en) Use of novel pan-cdk inhibitors for treating tumors
GEP20207106B (en) 18F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancer
EA201500851A1 (ru) ЭСТРА-1,3,5(10),16-ТЕТРАЕН-3-КАРБОКСАМИДЫ ДЛЯ ИНГИБИРОВАНИЯ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ (AKR1C3)
EA201490180A1 (ru) Антитела к erbb3 в комбинации с паклитакселом для лечения гинекологических злокачественных заболеваний
MX2016005393A (es) Metodos para tratar vhc.
MX2015004821A (es) Metodos y composiciones para tratar condiciones dependientes de la progesterona.
MX2013006732A (es) 19-noresteroides novedosos y su uso para tratar condiciones que dependen de progesterona.
IN2014MN01733A (es)
MX2016005511A (es) Intermediarios y metodos para sintetizar derivados de calicheamicina.
EA201491922A1 (ru) ВНУТРИМАТОЧНОЕ ПРИМЕНЕНИЕ 18-МЕТИЛ-15β,16β-МЕТИЛЕН-19-НОР-20-СПИРОКС-4-ЕН-3-ОНОВ, ВНУТРИМАТОЧНЫЕ СИСТЕМЫ, СОДЕРЖАЩИЕ 18-МЕТИЛ-15β,16β-МЕТИЛЕН-19-НОР-20-СПИРОКС-4-ЕН-3-ОНЫ, А ТАКЖЕ ИХ ПРИМЕНЕНИЕ ПРИ КОНТРАЦЕПЦИИ И ЛЕЧЕНИИ ГИНЕКОЛОГИЧЕСКИХ ЗАБОЛЕВАНИЙ